Everest Medicines, a Hong Kong-listed Chinese biopharmaceutical company, announced on Thursday that the National Medical Products Administration of China has approved its new drug application of Xerava, which is used for the treatment of complicated intra-abdominal infections in...
About the company Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The ...
Food and Drug Administration and European Medicines Agency. Today’s NMPA approval marks a new era of IgAN treatment in China. China has the highest prevalence of primary glomerular diseases in the world with an estimated five million I...
Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products ...
Chief Executive Officer of Everest Medicines. "The NDA approval further establishes our leadership position in nephrology. While the Company will actively prepare for the commercial launch of Nefecon® and bring this first-in-disease therapy ...
Everest Medicines announced that China's National Medical Products Administration has approved Nefecon® for the treatment of primary immunoglobulin A nephropathy in adults at risk of disease progression.
“We are eager for IgAN patients in China to gain access to this first-in-disease, innovative medicine, with support from favorable national pharmaceutical innovation policy and the Hainan Boao Lecheng Pilot Zone, " said Rogers Yongqing Luo, Chief Execu...
business development and operations both inChinaand with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which ...
Ms. Chui, has been an executive director of China Biotech Services Holdings Limited, a company listed on the GEM of the Stock Exchange (stock code: 8037), since December 2022. Previously, she was president of Harbin Pharmaceutical Group Co., Ltd. (“Harbin Pharmaceutical”), acompany listed...
Shanghai, China — March 28, 2024 — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today ...